Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efimosfermin alfa in MASH with suspected or known F2-F3 fibrosis
ISRCTN34498249Phase 3Recruiting
- Sponsor
- GSK
- Start
- Oct 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by GSK. Primary endpoint: Safety and tolerability. Started Oct 2025; status: recruiting.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on ISRCTN34498249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN34498249.